MetaCap

Allogene Therapeutics (ALLO) vs Scribe Therapeutics (SCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Scribe Therapeutics is the larger company by market cap ($228.6 million vs $217.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLO-64.13%SCTX-36.37%
+104%+16%-72%
Jul 27, 20261 yearNov 20, 2026
ALLO-66.61%SCTX-38.04%
+82%+4%-74%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLO versus SCTX key metrics
MetricALLOSCTX
Share price$0.6277$12.07
Market cap$217.48M$228.58M
1-day change-5.88%-8.70%
YTD return-54.18%—
1-year return-48.97%—
5-year return-96.51%—
EPS (TTM)$-0.61$-6.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-190.89M—
52-week high$4.46$39.60
52-week low$0.6192$12.00
Distance from 52-week high-85.93%-69.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1333.81%+372.25%
Average volume7.69M403.27K
Shares outstanding346.47M18.94M
Employees15077
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Allogene Therapeutics

ALLO stock →

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees

About Scribe Therapeutics

SCTX stock →

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees

ALLO vs SCTX FAQ

Which is bigger, Allogene Therapeutics or Scribe Therapeutics?

Scribe Therapeutics (SCTX) is larger, with a market capitalization of $228.58M compared with $217.48M for Allogene Therapeutics (ALLO).

Are Allogene Therapeutics and Scribe Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons